What is the current stock price of Arvinas, Inc. (ARVN)?

As of the latest market data, Arvinas, Inc. (ARVN) is trading at $10.82. The stock has seen a loss of -3.13% today.

Does Arvinas, Inc. (ARVN) pay a dividend?

Based on current data, Arvinas, Inc. does not have a confirmed active dividend policy.

What is the market cap of Arvinas, Inc.?

The current market capitalization of Arvinas, Inc. (ARVN) is approximately unavailable.

ARVN

Arvinas, Inc.·Healthcare

10.82

3.133%(−0.35)

Market Closed

14.00

29.390%(+3.18)

After Hours

Last Updated: — ET

52W L: $5.9052W H: $14.51

ARVN NEWS

defenseworld.net

3d ago

JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN

JPMorgan Chase and Co. lifted its holdings in Arvinas, Inc. (NASDAQ: ARVN) by 475.5% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 214,779 shares of the company's stock after buying an additional 177,460 shares during the period. JPMorgan Chase

zacks.com

Apr 2

Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?

Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

globenewswire.com

Mar 18

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days

– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy –

globenewswire.com

Mar 11

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease –

defenseworld.net

Mar 11

Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference

Arvinas (NASDAQ: ARVN) executives outlined a portfolio shift toward early-stage development and previewed multiple clinical catalysts in a discussion hosted by Barclays biotech analyst Esra Darroudi. Chief Executive Officer Randy Teel and Chief Scientific Officer Angela Cacace said the company is entering 2026 with four Phase 1 programs and expects clinical data for three of those

seekingalpha.com

Mar 10

Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Company Profile

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Sector

Healthcare

Industry

Biotechnology

Employees

430

IPO Date

2018-09-27

Beta

1.98

Websitewww.arvinas.com↗